DPP4 and myotonic dystrophy type 2: Dipeptidyl peptidase-IV (DPP-IV) inhibitors, as well as glucagon-like peptide-1 (GLP-1) agonists, are relatively new medications used in the treatment of DM2 where GLP-1 agonists, exenatide, and liraglutide were first introduced in the USA in 2005 and sitaglipitin, first DPP IV inhibitor introduced in 2006.